Serum Levels of Lipoprotein(a) and Homocysteine in Patients on Hemodialysis Who Take Hydroxymethylglutaryl- CoA Reductase Inhibitors, Vitamin B6, and Folic Acid

Shojaei, Mir Hatef; Djalali, Mamhmoud; Siassi, Fereydoun; Khatami, Mohammad Reza; Mohammad Ali Boroumand; Eshragian, Mohammad Reza
July 2009
Iranian Journal of Kidney Diseases;Jul2009, Vol. 3 Issue 3, p141
Academic Journal
Introduction. High serum levels of lipoprotein(a) and homocysteine are risk factors of cardiovascular disease which are prevalent in patients on hemodialysis. Controversy exists about the effects of hydroxymethylglutaryl-CoA reductase inhibitors on serum lipoprotein(a) levels in patients on hemodialysis. Also, deficiency of some water soluble vitamins and administration of statins may raise serum levels of homocysteine in these patients. This study was designed to investigate serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who were taking a statin, vitamin B6, and folic acid. Materials and Methods. We investigated on 152 patients with maintenance hemodialysis who were taking atorvastatin or lovastatin, vitamin B6, and folic acid for at least 6 months. Their serum levels were obtained to measure lipoprotein(a) and homocysteine levels, as well as triglyceride, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Results. The mean serum values of total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol and triglyceride were significantly less than the maximum reference values (P < .001). The mean serum level of lipoprotein(a) was also less than the reference value (P = .009), but homocysteine level was 33% higher on average than the reference value (P < .001). Conclusions. Our study demonstrated that in our patients on hemodialysis, the mean serum level of homocysteine was about 30% higher than the reference value although they were receiving vitamin B6 and folic acid. Hence, they were still exposed to the risk of cardiovascular disease.


Related Articles

  • Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement. Kolovou, Genovefa D.; Mikhailidis, Dimitri P.; Kovar, Jan; Lairon, Dennis; Nordestgaard, Børge G.; Ooi, Teik Chye; Perez-Martinez, Pablo; Bilianou, Helen; Anagnostopoulou, Katherine; Panotopoulos, George // Current Vascular Pharmacology;May2011, Vol. 9 Issue 3, p258 

    No abstract available.

  • Results of the 4D study: ten years of follow-up? Wanner, Christoph; Schmidt, Kai-Renke; Krane, Vera // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p274 

    Despite the exceedingly high cardiovascular risk in hemodialysis patients, it is uncertain whether statin regimens lead to clinical benefit in this population. KDIGO (Kidney Disease Improving Global Outcomes) guidelines summarize the evidence, stating that initiation of statin treatment is not...

  • Lipoprotein(a): Why is it important? Saeedi, Ramesh; Min Li; Frohlich, Jiri // British Columbia Medical Journal;May2014, Vol. 56 Issue 4, p180 

    Elevated lipoprotein(a) is an independent risk factor for cardiovascular disease, particularly in individuals with elevated low-density-lipoprotein cholesterol. Candidates for lipoprotein(a) screening include patients with familial hypercholesterolemia, those with personal or family history of...

  • Statins: The cause of much confusion. Hummerston, Gemma // British Journal of Cardiac Nursing;Jul2014, Vol. 9 Issue 7, p317 

    The author talks about the British National Institute for Health and Care Excellence draft on statin prescription and the debates that followed it because of the changes. She discusses the tweet she sent out from the "British Journal of Cardiac Nursing" Twitter account on the subject, and her...

  • Statin Therapy May Reduce HD Patients' CV Risks.  // Renal & Urology News;May2011, Vol. 10 Issue 5, p5 

    The article discusses a study which reveals that statin therapy may reduce the risk of all-cause mortality events in hemodialysis (HD) patients, such as cardiovascular (CV) diseases.

  • Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke. Munshi, Anjana // Human Genetics;Nov2012, Vol. 131 Issue 11, p1775 

    Statins reduce the risk of cardiovascular events by lowering the blood cholesterol. Many genes involved in the pharmacodynamic pathway of statins have been part of pharmacogenetic research in patients with hypercholesterolemia, with an emphasis on genes involved in the cholesterol pathway. The...

  • Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk. Jafri, Haseeb; Alsheikh-Ali, Alawi A.; Karas, Richard H. // Annals of Internal Medicine;12/21/2010, Vol. 153 Issue 12, p800 

    Background: Low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk for myocardial infarction (MI). Although statins reduce the risk for MI, most cardiovascular events still occur despite statin treatment. Purpose: Using meta-analysis of large randomized,...

  • Established and Emerging Approaches for the Management of Dyslipidaemia. Norata, Giuseppe Danilo // Scientifica;2012, p1 

    The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond reasonable doubt, and therefore several dietary and pharmacological approaches have been developed. The discovery of statins has provided a very effective approach in reducing cardiovascular risk as...

  • A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Mangravite, Lara M.; Engelhardt, Barbara E.; Medina, Marisa W.; Smith, Joshua D.; Brown, Christopher D.; Chasman, Daniel I.; Mecham, Brigham H.; Howie, Bryan; Shim, Heejung; Naidoo, Devesh; Feng, QiPing; Rieder, Mark J.; Chen, Yii.-Der I.; Rotter, Jerome I.; Ridker, Paul M.; Hopewell, Jemma C.; Parish, Sarah; Armitage, Jane; Collins, Rory; Wilke, Russell A. // Nature;10/17/2013, Vol. 502 Issue 7471, p377 

    Statins are prescribed widely to lower plasma low-density lipoprotein (LDL) concentrations and cardiovascular disease risk and have been shown to have beneficial effects in a broad range of patients. However, statins are associated with an increased risk, albeit small, of clinical myopathy and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics